Peter Gilbert, PhD

/content/dam/www/faculty-photos/G/peter-gilbert/peter-gilbert.jpg
Dr. Peter Gilbert PhD
FACULTY MEMBER

Peter Gilbert, PhD

Professor, Biostatistics, Bioinformatics and Epidemiology Program, Vaccine and Infectious Disease Division, Fred Hutch

Professor, Biostatistics, Bioinformatics and Epidemiology Program
Vaccine and Infectious Disease Division, Fred Hutch

Professor, Public Health Sciences Division, Fred Hutch

Professor
Public Health Sciences Division, Fred Hutch

Member, Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch

Member
Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch

Fax: 206.667.4812
Mail Stop: M2-C200

Dr. Peter Gilbert is a biostatistician engaged in the design and analysis of clinical trials of candidate vaccines for HIV and other infectious diseases. His team specializes in data analyses of these trials to understand how vaccine efficacy depends on immune responses to vaccination and on genetic features of infectious pathogens — a field of biostatistics he pioneered named “sieve analysis.” His teaching and research interests include general biostatistical methods in areas including survival analysis, causal inference and evaluation of surrogate endpoints. He enjoys working with biostatistics graduate students on innovative statistical methods for vaccine clinical trials.

Other Appointments & Affiliations

Principal Investigator, Statistical Data Management Center, HIV Vaccine Trials Network

Principal Investigator, Statistical Data Management Center
HIV Vaccine Trials Network

Research Professor, Biostatistics, University of Washington

Research Professor, Biostatistics
University of Washington

Graduate Faculty, Biostatistics, University of Washington

Graduate Faculty, Biostatistics
University of Washington

Education

University of Washington, 1996, PhD (Biostatistics)

University of Washington, 1994, MS (Biostatistics)

University of Washington, 1992, BS (Mathematics)

Research Interests

Vaccine clinical trials

Design and analysis of phase 2b vaccine clinical trials, for evaluating vaccine efficacy, immune correlates of protection, sieve analysis, and post-infection vaccine effects

Design and analysis of phase 2b/3 clinical trials of monoclonal antibodies for prevention of HIV infection

General biostatistical methods research, including survival analysis, causal inference, and evaluation of surrogate endpoints, especially involving immunology and virology data (e.g. pathogen sequences) integrated with clinical data

Current Projects

Leadership for the Statistical Data Management Center of the HIV Vaccine Trials Network and the Coronavirus Prevention Network

Statistical Methods in Vaccine Efficacy Trials for HIV, SARS-CoV-2, and Other Pathogens

Statistical Methods for Monoclonal Antibody HIV Prevention Efficacy Trials

Find a Clinical Trial

Dr. Gilbert in the News

SARS-CoV-2 vaccine efficacy in Latin American countries

Science Spotlight - April 17, 2024

Does HIV disease progression differ by ancestry?

Science Spotlight - September 19, 2022

Latest Fred Hutch research on COVID-19

Hutch News - June 30, 2022